- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06807268
Исследование лекарства, называемого абрацитинибом у детей от 6 до 12 лет, с экземой от средней до тяжелой степени
16-недельное многоцентровое, интервенционное, фаза 3, рандомизированное, двойное слепое, плацебо-контролируемое, параллельное групповое исследование для изучения эффективности и безопасности абрацитиниба у детей от 6 до менее 12 лет с атопическим дерматитом умеренной до тяжелой степени.
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.
Обзор исследования
Подробное описание
Different questionnaires will be used to find out how the participant's eczema is doing during the research study. An electronic diary, which looks like a cellular phone, will be used to collect the questionnaire information and other research study-related information. It will also be used to remind participants to take the test medicine each day and to fill out the questionnaires. Participants will also be asked to wear something on their wrist that looks like a children's wristwatch so we can know when they are scratching their skin because of their atopic dermatitis. Laboratory tests, physical examinations and vital signs (height, weight, temperature, blood pressure and heart rate) will be conducted before and during the research study to monitor your child's health. Participants will need to come to the clinic for research study visits and at other times during the research study, the research study doctor or nurse will call the participants to find out the participant is doing.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: Pfizer CT.gov Call Center
- Номер телефона: 1-800-718-1021
- Электронная почта: ClinicalTrials.gov_Inquiries@pfizer.com
Учебное резервное копирование контактов
- Имя: Nancy A Sherman, BA
- Номер телефона: 2127332323
- Электронная почта: Nancy.Sherman@Pfizer.com
Места учебы
-
-
-
Pécs, Венгрия, 7622
- Рекрутинг
- University of Pecs
-
-
Baranya
-
Pécs, Baranya, Венгрия, 7632
- Рекрутинг
- Pécsi Tudományegyetem Klinikai Központ
-
-
Bekes County
-
Békéscsaba, Bekes County, Венгрия, 5600
- Рекрутинг
- Trial Pharma Kft.
-
-
Csongrád-csanád
-
Szeged, Csongrád-csanád, Венгрия, 6720
- Рекрутинг
- Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika
-
-
Pest County
-
Budapest, Pest County, Венгрия, 1033
- Рекрутинг
- Clinexpert Kft.
-
-
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Германия, 48149
- Рекрутинг
- Universitätsklinikum Münster
-
-
Saxony
-
Dresden, Saxony, Германия, 01307
- Рекрутинг
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
-
-
-
-
-
Zaragoza, Испания, 50009
- Рекрутинг
- Hospital Universitario Miguel Servet
-
-
A Coruña [LA Coruña]
-
Santiago de Compostela, A Coruña [LA Coruña], Испания, 15706
- Рекрутинг
- CHUS - Hospital Clinico Universitario
-
-
Barcelona [barcelona]
-
Granollers, Barcelona [barcelona], Испания, 08402
- Рекрутинг
- Hospital General de Granollers
-
-
-
-
-
Shanghai, Китай, 200062
- Рекрутинг
- Shanghai Children's Hospital
-
Shanghai, Китай, 200092
- Рекрутинг
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100045
- Рекрутинг
- Beijing Children's hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen, Guangdong, Китай, 518026
- Рекрутинг
- Shenzhen Children's Hospital
-
-
Hunan
-
Changsha, Hunan, Китай, 410007
- Рекрутинг
- Hunan Children's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 330000
- Рекрутинг
- Dermatology Hospital of Jiangxi Province
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200040
- Рекрутинг
- Shanghai Children's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай, 310009
- Рекрутинг
- Hangzhou Third People's Hospital
-
-
-
-
-
Chihuahua City, Мексика, 31238
- Рекрутинг
- Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)
-
-
Mexico City
-
Mexico City, Mexico City, Мексика, 06720
- Рекрутинг
- Hospital Infantil de México Federico Gómez
-
-
Nuevo León
-
Monterrey, Nuevo León, Мексика, 64718
- Рекрутинг
- Eukarya Pharmasite S.C.
-
-
Veracruz
-
Veracruz, Veracruz, Мексика, 91900
- Рекрутинг
- Arke SMO S.A. de C.V.
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Польша, 30-002
- Рекрутинг
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Польша, 20-573
- Рекрутинг
- LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Польша, 02-625
- Рекрутинг
- Centrum Medyczne Evimed
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, Польша, 41-500
- Рекрутинг
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
-
Katowice, Silesian Voivodeship, Польша, 40-611
- Рекрутинг
- Centrum Medyczne Angelius Provita
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Польша, 90-436
- Рекрутинг
- Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Польша, 27-400
- Рекрутинг
- Dermedic Jacek Zdybski
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35244
- Рекрутинг
- Cahaba Dermatology & Skin Health Center, LLC
-
-
Arkansas
-
North Little Rock, Arkansas, Соединенные Штаты, 72117
- Рекрутинг
- Arkansas Research Trials
-
-
California
-
San Diego, California, Соединенные Штаты, 92123
- Рекрутинг
- Investigational Drug Service - Rady Childrens Hospital-San Diego
-
San Diego, California, Соединенные Штаты, 92123
- Рекрутинг
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Рекрутинг
- Solutions Through Advanced Research
-
-
Idaho
-
Meridian, Idaho, Соединенные Штаты, 83646
- Рекрутинг
- Ada West Research
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46250
- Рекрутинг
- Dawes Fretzin Clinical Research Group, LLC
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63104
- Рекрутинг
- Saint Louis University - Department of Dermatology
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Рекрутинг
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Рекрутинг
- Medical University of South Carolina - Department of Dermatology
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Рекрутинг
- Medical University of South Carolina - Walton Research Building
-
Greenville, South Carolina, Соединенные Штаты, 29607
- Рекрутинг
- Tribe Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, Соединенные Штаты, 78235
- Рекрутинг
- Texas Dermatology and Laser Specialists
-
-
-
-
-
Fukuoka, Япония, 811-1394
- Рекрутинг
- Fukuoka National Hospital
-
Fukuoka, Япония, 819-0042
- Рекрутинг
- Saruta Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, Япония, 220-6208
- Рекрутинг
- Queen's square Medical Facilities Queen's square Dermatology and Allergology
-
-
Osaka
-
Sakai, Osaka, Япония, 593-8324
- Рекрутинг
- Dermatology and Ophthalmology Kume Clinic
-
-
Tokyo
-
Setagaya-ku, Tokyo, Япония, 157-0066
- Рекрутинг
- Sasamoto Children's Clinic
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria Children aged 6 to <12 years at the time of informed consent/assent.
• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.
Disease Characteristics:
Participants who meet all of the following AD criteria:
- A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
- A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy
Other Inclusion Criteria:
Body weight ≥15 kg
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
Have any of the following medical conditions:
-
Infections:
- Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
- History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
- Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- Infection with HIV, hepatitis B, and/or hepatitis C
- Evidence of active TB or inadequately treated latent TB.
-
Skin Conditions:
- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
-
Other Conditions:
- Documented history of skeletal dysplasia.
- Documented history of retinal detachment.
- History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
Prior/Concomitant Therapy:
Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.
Prior/Concurrent Clinical Study Experience:
Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Abrocitinib
Abrocitinib administered as liquid oral suspension. |
Abrocitinib administered as liquid oral suspension.
Другие имена:
|
|
Плацебо Компаратор: Matching Placebo
Placebo administered as liquid oral suspension. |
Placebo administered as liquid oral suspension. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
Временное ограничение: At week 12
|
The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
|
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
Временное ограничение: At week 12
|
The difference in proportion of responders based on EASI-75 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from Baseline (CFB) in the Worst Itch Numerical Rating Scale (WI-NRS) at Week 2
Временное ограничение: At week 2
|
The difference in mean CFB in WI-NRS total score at Week 2 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 2
|
|
Response based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12
Временное ограничение: At week 12
|
The difference in proportion of responders based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
|
Response based on achieving WI-NRS <2 at Week 12
Временное ограничение: At week 12
|
The difference in proportion of responders based on achieving WI-NRS <2 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Pfizer CT.gov Call Center, Pfizer
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- B7451023
- 2023-509121-51-00 (Идентификатор реестра: CTIS (EU))
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .